Par Drugs & Chemicals Ltd (PAR) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1003142,
    "name": "Par Drugs & Che.",
    "stock_name": "Par Drugs & Che.",
    "full_name": "Par Drugs & Chemicals Ltd",
    "name_url": "stocks-analysis/par-drugs-che",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "91.54",
    "chg": -0.79,
    "chgp": "-0.86%",
    "dir": -1,
    "prev_price": "92.33",
    "mcapval": "114.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "PAR",
    "ind_name": "Chemicals & Petrochemicals",
    "ind_code": 11,
    "indexname": "",
    "isin": "INE04LG01015",
    "curr_date": "Jan 19",
    "curr_time": "",
    "bse_nse_vol": 5612,
    "exc_status": "Active",
    "traded_date": "Jan 19, 2026",
    "traded_date_str": "2026 01 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/par-drugs-che-1003142-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Par Drugs & Chemicals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/par-drugs-chemicals-ltd-is-rated-sell-3783059",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/1/ParDrugsChemica_mojoScore_3783059.png",
        "date": "2026-01-06 10:10:43",
        "description": "Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Par Drugs & Chemicals Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/par-drugs-chemicals-ltd-is-rated-sell-3769590",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ParDrugsChemica_mojoScore_3769590.png",
        "date": "2025-12-25 15:13:16",
        "description": "Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook."
      },
      {
        "title": "Par Drugs & Che. Sees Revision in Market Assessment Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/par-drugs-che-upgraded-from-strong-sell-to-sell-by-marketsmojo-3748059",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ParDrugsChe_mojoScore_3748059.png",
        "date": "2025-12-05 10:11:01",
        "description": "Par Drugs & Che., a microcap player in the Chemicals & Petrochemicals sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This development comes amid a volatile performance trajectory and evolving market conditions."
      },
      {
        "title": "Is Par Drugs & Che. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-par-drugs-che-overvalued-or-undervalued-3710201",
        "imagepath": "",
        "date": "2025-11-18 08:29:41",
        "description": "As of 17 November 2025, the valuation grade for Par Drugs & Chemicals has moved from very attractive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 11.95, an EV to EBIT of 8.99, and an ROCE of 22.22%. \n\nIn comparison to its peers, Par Drugs & Chemicals has a PE ratio significantly lower than Solar Industries at 95.31 and Gujarat Fluoroch at 57.85, both of which are deemed very expensive. Additionally, the company’s EV to EBITDA of 6.54 is more favorable than that of Godrej Industries, which stands at 40.96, classified as attractive. Notably, Par Drugs & Chemicals has underperformed the Sensex significantly over the past year, with a stock return of -65.29% compared to the Sensex's 10.54%, reinforcing the notion that the stock may be fairly valued at present...."
      },
      {
        "title": "Par Drugs & Chemicals Q2 FY26: Profit Rebound Masks Underlying Margin Pressure",
        "link": "https://www.marketsmojo.com/news/result-analysis/par-drugs-chemicals-q2-fy26-profit-rebound-masks-underlying-margin-pressure-3718448",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/ParDrugsChemica_quaterlyResult_3718448.png",
        "date": "2025-11-15 10:58:28",
        "description": "Par Drugs and Chemicals Ltd., a micro-cap speciality chemicals manufacturer based in Gujarat, reported a sequential profit recovery in Q2 FY26, with net profit climbing to ₹4.13 crores from ₹3.33 crores in the previous quarter. However, the year-on-year comparison reveals a more sobering reality: profits plunged 51.98% from ₹8.60 crores in Q2 FY25, whilst the company's stock has witnessed a brutal correction, trading at ₹93.70—down 73.11% from its 52-week high of ₹348.45."
      },
      {
        "title": "How has been the historical performance of Par Drugs & Che.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-par-drugs-che-3699683",
        "imagepath": "",
        "date": "2025-11-13 23:46:17",
        "description": "Answer:\nThe historical performance of Par Drugs & Che. shows a consistent growth trend in net sales and profits over the years, with some fluctuations in specific metrics.\n\nBreakdown:\nPar Drugs & Che. has demonstrated a steady increase in net sales, rising from 55.85 Cr in Mar'20 to 100.97 Cr in Mar'25. Total operating income has followed a similar trajectory, reaching 100.97 Cr in Mar'25, up from 46.32 Cr in Mar'19. The company's total expenditure, excluding depreciation, increased to 81.47 Cr in Mar'25 from 38.12 Cr in Mar'19, reflecting rising costs, particularly in raw materials, which amounted to 39.41 Cr in Mar'25. Operating profit (PBDIT) has shown variability, peaking at 23.06 Cr in Mar'24 before declining to 21.65 Cr in Mar'25. Profit before tax reached 17.92 Cr in Mar'25, while profit after tax was 13.36 Cr, indicating a healthy profit margin of 13.23%. The company's total assets grew significantl..."
      },
      {
        "title": "Why is Par Drugs & Che. falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-par-drugs-che-fallingrising-3681600",
        "imagepath": "",
        "date": "2025-11-08 00:05:41",
        "description": "As of 07-Nov, Par Drugs & Chemicals Ltd is experiencing a decline in its stock price, currently at 98.73, reflecting a decrease of 0.45 or 0.45%. The stock has underperformed its sector by 0.49% today and is trading below all major moving averages, indicating a bearish trend. Over the past week, the stock has dropped by 3.37%, and its year-to-date performance shows a significant decline of 50.36%. Despite a low debt-to-equity ratio and an attractive valuation with a price-to-book value of 1.2, the company has reported negative results for the last three consecutive quarters, contributing to a substantial 67.00% drop in returns over the past year. Additionally, the company's net sales growth has been modest at 12.10% annually over the last five years, and its profits have decreased by 2.8%, further impacting investor sentiment.\n\nIn the broader market context, the Sensex has shown a slight increase of 7.81% y..."
      }
    ],
    "total": 104,
    "sid": "1003142",
    "stock_news_url": "https://www.marketsmojo.com/news/par-drugs-chemicals-1003142"
  },
  "announcements": [
    {
      "details": "Par Drugs And Chemicals Limited has informed the Exchange regarding Board meeting held on November 11, 2019.",
      "source": "NSE",
      "caption": "Par Drugs And Chemicals Limited - Outcome of Board Meeting",
      "datetime": "13-Nov-2019"
    },
    {
      "details": "Par Drugs And Chemicals Limited has informed the Exchange that the Company has fixed Record Date as November 25, 2019 for the purpose of INTERIM DIVIDEND",
      "source": "NSE",
      "caption": "Par Drugs And Chemicals Limited - Record Date",
      "datetime": "04-Nov-2019"
    },
    {
      "details": "Par Drugs And Chemicals Limited has informed the Exchange regarding 'WHO-GMP Certification'.",
      "source": "NSE",
      "caption": "Par Drugs And Chemicals Limited - Updates",
      "datetime": "30-Oct-2019"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Par Drugs & Chemicals Ltd has declared <strong>12%</strong> dividend, ex-date: 22 Nov 21",
          "dt": "2021-11-22",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Par Drugs & Chemicals Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 27 Apr 21",
          "dt": "2021-04-27",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Par Drugs & Chemicals Ltd is Rated Sell

2026-01-06 10:10:43

Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Par Drugs & Chemicals Ltd is Rated Sell

2025-12-25 15:13:16

Par Drugs & Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 10 May 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Read full news article

Par Drugs & Che. Sees Revision in Market Assessment Amid Mixed Financial Signals

2025-12-05 10:11:01

Par Drugs & Che., a microcap player in the Chemicals & Petrochemicals sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This development comes amid a volatile performance trajectory and evolving market conditions.

Read full news article

Is Par Drugs & Che. overvalued or undervalued?

2025-11-18 08:29:41

As of 17 November 2025, the valuation grade for Par Drugs & Chemicals has moved from very attractive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 11.95, an EV to EBIT of 8.99, and an ROCE of 22.22%. In comparison to its peers, Par Drugs & Chemicals has a PE ratio significantly lower than Solar Industries at 95.31 and Gujarat Fluoroch at 57.85, both of which are deemed very expensive. Additionally, the company’s EV to EBITDA of 6.54 is more favorable than that of Godrej Industries, which stands at 40.96, classified as attractive. Notably, Par Drugs & Chemicals has underperformed the Sensex significantly over the past year, with a stock return of -65.29% compared to the Sensex's 10.54%, reinforcing the notion that the stock may be fairly valued at present....

Read full news article

Par Drugs & Chemicals Q2 FY26: Profit Rebound Masks Underlying Margin Pressure

2025-11-15 10:58:28

Par Drugs and Chemicals Ltd., a micro-cap speciality chemicals manufacturer based in Gujarat, reported a sequential profit recovery in Q2 FY26, with net profit climbing to ₹4.13 crores from ₹3.33 crores in the previous quarter. However, the year-on-year comparison reveals a more sobering reality: profits plunged 51.98% from ₹8.60 crores in Q2 FY25, whilst the company's stock has witnessed a brutal correction, trading at ₹93.70—down 73.11% from its 52-week high of ₹348.45.

Read full news article

How has been the historical performance of Par Drugs & Che.?

2025-11-13 23:46:17

Answer: The historical performance of Par Drugs & Che. shows a consistent growth trend in net sales and profits over the years, with some fluctuations in specific metrics. Breakdown: Par Drugs & Che. has demonstrated a steady increase in net sales, rising from 55.85 Cr in Mar'20 to 100.97 Cr in Mar'25. Total operating income has followed a similar trajectory, reaching 100.97 Cr in Mar'25, up from 46.32 Cr in Mar'19. The company's total expenditure, excluding depreciation, increased to 81.47 Cr in Mar'25 from 38.12 Cr in Mar'19, reflecting rising costs, particularly in raw materials, which amounted to 39.41 Cr in Mar'25. Operating profit (PBDIT) has shown variability, peaking at 23.06 Cr in Mar'24 before declining to 21.65 Cr in Mar'25. Profit before tax reached 17.92 Cr in Mar'25, while profit after tax was 13.36 Cr, indicating a healthy profit margin of 13.23%. The company's total assets grew significantl...

Read full news article

Why is Par Drugs & Che. falling/rising?

2025-11-08 00:05:41

As of 07-Nov, Par Drugs & Chemicals Ltd is experiencing a decline in its stock price, currently at 98.73, reflecting a decrease of 0.45 or 0.45%. The stock has underperformed its sector by 0.49% today and is trading below all major moving averages, indicating a bearish trend. Over the past week, the stock has dropped by 3.37%, and its year-to-date performance shows a significant decline of 50.36%. Despite a low debt-to-equity ratio and an attractive valuation with a price-to-book value of 1.2, the company has reported negative results for the last three consecutive quarters, contributing to a substantial 67.00% drop in returns over the past year. Additionally, the company's net sales growth has been modest at 12.10% annually over the last five years, and its profits have decreased by 2.8%, further impacting investor sentiment. In the broader market context, the Sensex has shown a slight increase of 7.81% y...

Read full news article

View All News